Skip to main content
Premium Trial:

Request an Annual Quote

Atlas Genetics Raises $35M in Series D Fundraising

NEW YORK (GenomeWeb) ­– Atlas Genetics announced today that it has completed a $35 million Series D financing round.

All of Atlas' Series C round investors — who contributed $20 million in January 2015 — participated in the Series D round. These include Novartis Venture Funds, Consort Medical, Johnson & Johnson Innovation - JJDC, Inc, Life Science Partners, BB Biotech Ventures, RMI Partners, and Technology Venture Partners.

The company also had one new investor — Chinese in vitro diagnostic assay developer Wondfo Biotech, based in Guangzhou, Guangdong Province.

Atlas announced that it had received CE marking on its rapid point-of-care io molecular diagnostic system and Chlamydia trachomatis assay last year. The new funding will now finance clinical trials and commercial launch of a combined test for chlamydia and gonorrhea, the company said, adding that it intends to seek regulatory approvals in the US for the CT/NG test near the end of 2017.

Part of the funding will also be applied toward menu expansion for the io system as well as increasing cartridge manufacturing capacity.

"We believe that Atlas Genetics is poised to become a world leader in POC molecular diagnostics and we plan to roll out new assays in a range of clinical areas over the next two years and beyond," Atlas CEO John Clarkson said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more